NMPA Registration
China's medical device registration system, among the most demanding globally for higher-risk devices.
Overview
What NMPA is and why it matters
China's National Medical Products Administration (NMPA) regulates devices under a three-class risk system. Class II and III devices generally require type testing at NMPA-accredited laboratories and, in most cases, clinical evaluation or trials conducted within China — a requirement that sets NMPA apart from reliance-based regulators and typically extends timelines well beyond other major markets.
Requirements
What you'll need
- Device classification (Class I–III)
- Local agent / legal representative in China
- Type testing at NMPA-accredited laboratories
- Clinical evaluation or in-country clinical trial for most Class II/III devices
- Registration certificate renewal every 5 years
Typical timeline
12–36 months
Among the longest timelines in this database — in-country clinical and testing requirements for higher-risk devices are the main driver.
Estimated cost
$30k–$300k
In-country clinical trials, where required, are the largest cost driver by a wide margin.
Where this applies
Applicable countries
Related
Regulatory Pathways
FAQ
Frequently asked questions
Can I use my CE or FDA clinical data in China?+
Sometimes, under narrowing exemption criteria — but most Class II/III devices still require some form of China-specific clinical evaluation or trial; this should be confirmed for your specific device with a China-qualified regulatory professional.
Reviewed launch planning
Ready to start your NMPA project?
GHMAP structures your certification path, evidence gaps, and next actions — then connects you with a qualified consultant if you need one.
Professional review remains part of the workflow.